Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
2022 · Nature Medicine · 76 citations
https://doi.org/10.1038/s41591-022-01696-4
J
Justin P. Ingram
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
33
Papers
1.7K
Citations
10
h-index
10
i10-index
Justin P. Ingram is an academic researcher from AbbVie (United States). The author has contributed to research in topics: Ferroptosis and cancer prognosis & interferon and immune responses & Clusterin in disease pathology. The author has an h-index of 10, co-authored 29 publications.
ORCID: 0009-0009-0152-4811Papers by this author
worksMP77-04 DURABILITY OF CLINICAL COMPLETE RESPONSE TO NAC FOR MIBC WITH ADVERSE PATHOLOGIC FEATURES
2024 · The Journal of Urology · 0 citations
https://doi.org/10.1097/01.ju.0001009404.49693.12.04
LP-40 Launch of the DIM testing project: when animal testing is difficult, impossible and meaningless (DIM) and implications for REACH regulation
2025 · Toxicology Letters · 0 citations
https://doi.org/10.1016/j.toxlet.2025.07.1054
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat